VanEck Biotech ETFBBH
BBH
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,174% more call options, than puts
Call options by funds: $2.61M | Put options by funds: $205K
2.42% less ownership
Funds ownership: 37.14% [Q4 2024] → 34.73% (-2.42%) [Q1 2025]
12% less funds holding
Funds holding: 112 [Q4 2024] → 99 (-13) [Q1 2025]
14% less capital invested
Capital invested by funds: $148M [Q4 2024] → $127M (-$20.5M) [Q1 2025]
58% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 36
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Research analyst outlook
We haven’t received any recent analyst ratings for BBH.
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Negative
Seeking Alpha
1 month ago
BBH: Fear Of Price Controls Is Not The Problem
The executive order aims to reduce drug prices by allowing direct sales to consumers and cutting out PBMs but faces significant challenges. The main risk for biotech is FDA approval delays due to skepticism from newly appointed officials, impacting funding and development. The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk.
Neutral
Zacks Investment Research
1 month ago
Should You Invest in the VanEck Biotech ETF (BBH)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on 12/20/2011.
Neutral
Seeking Alpha
3 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Neutral
Zacks Investment Research
3 months ago
Should You Invest in the VanEck Biotech ETF (BBH)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on 12/20/2011.
Neutral
Zacks Investment Research
5 months ago
Should You Invest in the VanEck Biotech ETF (BBH)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on 12/20/2011.
Neutral
Business Wire
5 months ago
VanEck Announces Year-End Distributions for VanEck Equity ETFs
NEW YORK--(BUSINESS WIRE)--VanEck has announced the 2024 annual distributions per share for its VanEck equity exchange-traded funds (ETFs).
Neutral
Zacks Investment Research
7 months ago
Should You Invest in the VanEck Biotech ETF (BBH)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on 12/20/2011.
Neutral
Zacks Investment Research
9 months ago
Should You Invest in the VanEck Biotech ETF (BBH)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on 12/20/2011.
Positive
Seeking Alpha
10 months ago
BBH: Buy Rating, As Tech Investors Look Beyond FAANG
Biotechnology sector experiencing exponential growth driven by emerging technologies addressing global challenges. VanEck Biotech ETF tracks top U.S.-listed biotech companies, offers exposure to innovative therapies and technologies. BBH is under-discovered compared to peers, offers potential for trend change in favor of biotech sector.
Charts implemented using Lightweight Charts™